Quintet Private Bank Europe S.A. Grows Stock Position in Merck & Co., Inc. $MRK

Key Points

• Quintet Private Bank Europe increased its Merck position by 19.9% in the third quarter, adding 56,052 shares for a total of 337,040 shares valued at approximately $49 million. Institutional investors collectively own 76.07% of Merck.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $151.32, above the reported share price of $141.11.
• Merck’s outlook is supported by Keytruda demand, new products and pipeline assets, but investors face risks from patent expirations, generic competition and a Dutch court ruling blocking the subcutaneous Keytruda formulation in eight European markets.

Quintet Private Bank Europe S.A. boosted its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 19.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 337,040 shares of the company's stock after purchasing an additional 56,052 shares during the period. Merck & Co., Inc. accounts for approximately 2.3% of Quintet Private Bank Europe S.A.'s holdings, making the stock its 12th largest holding. Quintet Private Bank Europe S.A.'s holdings in Merck & Co., Inc. were worth $48,975,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Abound Financial LLC bought a new stake in Merck & Co., Inc. during the 4th quarter worth about $26,000. Bullseye Investment Management LLC bought a new stake in shares of Merck & Co., Inc. during the second quarter valued at approximately $27,000. Horizons Wealth Management acquired a new stake in shares of Merck & Co., Inc. in the third quarter valued at approximately $30,000. Graney & King LLC raised its position in Merck & Co., Inc. by 400.0% in the 2nd quarter. Graney & King LLC now owns 250 shares of the company's stock worth $32,000 after purchasing an additional 200 shares during the last quarter. Finally, Montgomery Financial Services LLC bought a new position in Merck & Co., Inc. in the 2nd quarter worth approximately $41,000. Institutional investors own 76.07% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on MRK. TD Cowen increased their price objective on Merck & Co., Inc. from $137.00 to $155.00 and gave the company a "hold" rating in a research report on Wednesday, September 23rd. Wells Fargo & Company upped their price target on Merck & Co., Inc. from $150.00 to $170.00 and gave the company an "overweight" rating in a research note on Friday, September 4th. Sanford C. Bernstein raised their price target on Merck & Co., Inc. from $100.00 to $105.00 and gave the company a "market perform" rating in a report on Tuesday, August 4th. Wall Street Zen cut Merck & Co., Inc. from a "buy" rating to a "hold" rating in a report on Saturday, October 3rd. Finally, Guggenheim raised their target price on shares of Merck & Co., Inc. from $146.00 to $170.00 and gave the company a "buy" rating in a research note on Tuesday, September 8th. Seventeen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, Merck & Co., Inc. has an average rating of "Moderate Buy" and a consensus target price of $151.32.

Insider Buying and Selling at Merck & Co., Inc.

In related news, EVP Richard Deluca sold 20,784 shares of the business's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the completion of the transaction, the executive vice president owned 134,703 shares in the company, valued at approximately $17,569,312.29. The trade was a 13.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP David Maraldo sold 18,706 shares of the company's stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the sale, the executive vice president directly owned 18,212 shares of the company's stock, valued at $2,344,248.64. The trade was a 50.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 228,238 shares of company stock worth $29,977,783 over the last ninety days. 0.17% of the stock is owned by corporate insiders.

Merck & Co., Inc. Trading Down 1.2%

Shares of NYSE:MRK traded down $1.68 during midday trading on Thursday, hitting $141.11. The company had a trading volume of 2,345,448 shares, compared to its average volume of 10,629,651. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a 12 month low of $82.01 and a 12 month high of $156.92. The firm has a fifty day simple moving average of $143.34 and a 200 day simple moving average of $127.96. The stock has a market cap of $348.15 billion, a price-to-earnings ratio of 112.71, a PEG ratio of 6.18 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter in the prior year, the company posted $2.13 earnings per share. The firm's revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, analysts predict that Merck & Co., Inc. will post 2.76 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were given a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date was Tuesday, September 15th. Merck & Co., Inc.'s dividend payout ratio (DPR) is currently 272.00%.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst targets remain above the stock price. Cantor Fitzgerald raised its price target from $120 to $145 while maintaining a neutral rating. Morgan Stanley trimmed its target from $179 to $177 but retained an overweight rating, implying substantial potential upside. Cantor Fitzgerald raises pharma price targets
• Positive Sentiment: Longer-term growth arguments remain intact. Recent analysis points to continued Keytruda demand, newer products and pipeline assets as potential support for Merck’s outlook after 2028, helping offset concerns about upcoming patent expirations. Merck stock dip and buying opportunity analysis
• Neutral Sentiment: Merck paid its shareholder distribution. The dividend reinforces Merck’s income appeal, although the payment itself is unlikely to materially change the company’s near-term earnings outlook. Merck shareholder payment
• Negative Sentiment: A Dutch court sided with Halozyme Therapeutics in a patent dispute, barring Merck from selling subcutaneous Keytruda in eight European markets. The ruling threatens the rollout of a more convenient formulation of Merck’s key cancer drug and could increase investor concern about competitive and patent-related risks. Merck may appeal. Merck Keytruda European legal setback
• Negative Sentiment: Merck is viewed as the pharmaceutical company most exposed to near-term generic competition. Analysts expect industrywide patent losses to arrive in waves, raising concerns about revenue durability and the need for successful replacement products. Pharmaceutical patent losses and Merck exposure

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.